Nokia Corporation (NOK)
On September 3, 2013, Microsoft Corporation and NOK reported that the Boards of Directors for both companies have decided to enter into a transaction whereby Microsoft will purchase substantially all of NOK 's Devices & Services business, license NOK 's patents, and license and use NOK 's mapping services.
Under the terms of the agreement, Microsoft will pay EUR 3.79 billion to purchase substantially all of NOK 's Devices & Services business, and EUR 1.65 billion to license NOK 's patents, for a total transaction price of EUR 5.44 billion in cash.
NOK reported today that it has received regulatory approval from the Ministry of Commerce of the People's Republic of China to sell its mobile phone business to Microsoft Corp.
The closing of the transaction is subject to regulatory approvals and other customary closing conditions. NOK and Microsoft have now received regulatory approvals from the People's Republic of China, the European Commission, the U.S. Department of Justice and numerous other jurisdictions.
NOK and Microsoft continue to expect the transaction to close during April 2014
NOK is a global leader in mobile communications whose products have become an integral part of the lives of people around the world.
More about Nokia Corporation (NOK) at www.nokia.com
**
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
CRWE is currently developing its CRWE Network ( CRWE-PR.com ), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.
Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 365th community website in the U.S., associated with 1680 ZIP Codes , and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada
CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
TherapeuticsMD, Inc. (TXMD)
The North American Menopause Society (NAMS) estimates that up to 50% of postmenopausal women are affected by Vulvar and vaginal atrophy (VVA), which results from the decrease in estrogen that occurs with menopause. Symptoms include dyspareunia (pain with intercourse), vaginal dryness, and irritation and may affect sexual activities, relationships, and activities of daily life.
The U.S. Census estimates the number of postmenopausal women in the U.S. will exceed 50 million in 2015.
TXMD reported positive results of a rabbit irritation study for its TX 004-HR, a rapidly acting estrogen vaginal preparation capsule (VagiCap)
This toxicity study involved vaginal administration of VagiCap in New Zealand white female rabbits. The study demonstrated that TX 004-HR was "non-irritant" following a 28-day repeated application to the vaginal mucosa.
This toxicity study was conducted to meet a specific FDA requirement for any new component of a novel delivery system, such as the VagiCap vaginal softgel capsule for estradiol. Because the components of the VagiCap had not been previously studied in vaginal delivery, the capsule was required to pass this local toxicity assessment at repeated doses.
TX 004-HR estradiol VagiCap is an investigational drug enabling the vaginal administration of estradiol that is designed to treat moderate to severe VVA symptoms associated with menopause. TX 004-HR leverages the solubilized estradiol technology developed by TXMD in a unique, tear-shaped softgel capsule designed for easy intravaginal insertion.
** TXMD 's TX 004-HR estradiol VagiCap is the first softgel capsule for the treatment of VVA being developed for review by the FDA **
Source Healthcare Analytics estimated the U.S. market for postmenopausal VVA was over $1 billion in 2013, increasing more than 20% over the prior year. GlobalData currently projects the global market for postmenopausal VVA will reach $3.1 billion by 2019.
TXMD is a specialty pharmaceutical company focused on creating safe and effective branded prescription, generic prescription, and over-the-counter (non-prescription) products targeted exclusively for women.
More about TherapeuticsMD, Inc. (TXMD) at www.therapeuticsmd.com
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
